{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-03-18",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "New York",
      "state": "NY",
      "country": "United States",
      "classification": "Class II",
      "openfda": {
        "application_number": [
          "NDA021301"
        ],
        "brand_name": [
          "LEVOXYL"
        ],
        "generic_name": [
          "LEVOTHYROXINE SODIUM"
        ],
        "manufacturer_name": [
          "Pfizer Laboratories Div Pfizer Inc"
        ],
        "product_ndc": [
          "60793-850",
          "60793-851",
          "60793-852",
          "60793-853",
          "60793-854",
          "60793-855",
          "60793-856",
          "60793-857",
          "60793-858",
          "60793-859",
          "60793-860"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "ORAL"
        ],
        "substance_name": [
          "LEVOTHYROXINE SODIUM"
        ],
        "rxcui": [
          "892246",
          "892251",
          "966157",
          "966164",
          "966170",
          "966175",
          "966184",
          "966190",
          "966194",
          "966200",
          "966204",
          "966211",
          "966220",
          "966221",
          "966222",
          "966224",
          "966225",
          "966248",
          "966249",
          "966253",
          "966270",
          "966283"
        ],
        "spl_id": [
          "e230c170-2a16-47d0-bce7-ac0414c192f7"
        ],
        "spl_set_id": [
          "758588c3-c63e-491b-0aa2-4f50d80cb174"
        ],
        "package_ndc": [
          "60793-850-10",
          "60793-850-01",
          "60793-851-10",
          "60793-851-01",
          "60793-852-10",
          "60793-852-01",
          "60793-853-10",
          "60793-853-01",
          "60793-854-10",
          "60793-854-01",
          "60793-855-10",
          "60793-855-01",
          "60793-856-10",
          "60793-856-01",
          "60793-857-10",
          "60793-857-01",
          "60793-858-10",
          "60793-858-01",
          "60793-859-10",
          "60793-859-01",
          "60793-860-10",
          "60793-860-01"
        ],
        "is_original_packager": [
          true
        ],
        "upc": [
          "0360793856018",
          "0360793850016",
          "0360793852010",
          "0360793851013",
          "0360793857015",
          "0360793853017",
          "0360793854014",
          "0360793858012",
          "0360793855011",
          "0360793859019",
          "0360793860015"
        ],
        "unii": [
          "9J765S329G"
        ]
      },
      "product_type": "Drugs",
      "event_id": "81731",
      "recalling_firm": "Pfizer Inc.",
      "address_1": "235 E 42nd St",
      "address_2": "",
      "postal_code": "10017-5703",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Nationwide within the United States",
      "recall_number": "D-0339-2019",
      "product_description": "Levoxyl (levothyroxine sodium tablets, USP) tablets 112 mcg, 100-count bottle,  Rx Only,Distributed by Pfizer Inc. New York, NY 10017, NDC 60793-855-01",
      "product_quantity": "1996 bottles",
      "reason_for_recall": "Superpotent Drug.",
      "recall_initiation_date": "20181206",
      "center_classification_date": "20181218",
      "termination_date": "20201008",
      "report_date": "20181226",
      "code_info": "Lot #:18A18, Exp. 01/2020",
      "more_code_info": ""
    }
  ]
}